Unjoni Ewropea -
Malti -
EMA (European Medicines Agency)
tresiba
novo nordisk a/s - insulina degludec - diabetes mellitus - drogi użati fid-dijabete - trattament tad-dijabete mellitus fl-adulti.
Unjoni Ewropea -
Malti -
EMA (European Medicines Agency)
actraphane
novo nordisk a/s - insulin human - diabetes mellitus - drogi użati fid-dijabete - trattament tad-dijabete mellitus.
Unjoni Ewropea -
Malti -
EMA (European Medicines Agency)
mixtard
novo nordisk a/s - insulin human - diabetes mellitus - drogi użati fid-dijabete - trattament tad-dijabete mellitus.
Unjoni Ewropea -
Malti -
EMA (European Medicines Agency)
novomix
novo nordisk a/s - insulin aspart - diabetes mellitus - drogi użati fid-dijabete - trattament tad-dijabete mellitus.
Unjoni Ewropea -
Malti -
EMA (European Medicines Agency)
kirsty (previously kixelle)
biosimilar collaborations ireland limited - insulin aspart - diabetes mellitus - drogi użati fid-dijabete - kirsty is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
Unjoni Ewropea -
Malti -
EMA (European Medicines Agency)
truvelog mix 30
sanofi winthrop industrie - insulin aspart - diabetes mellitus - drogi użati fid-dijabete - truvelog mix 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above.
Unjoni Ewropea -
Malti -
EMA (European Medicines Agency)
insulatard
novo nordisk a/s - insulin human - diabetes mellitus - drogi użati fid-dijabete - trattament tad-dijabete mellitus.
Unjoni Ewropea -
Malti -
EMA (European Medicines Agency)
protaphane
novo nordisk a/s - insulin human - diabetes mellitus - drogi użati fid-dijabete - trattament tad-dijabete mellitus.
Unjoni Ewropea -
Malti -
EMA (European Medicines Agency)
velosulin
novo nordisk a/s - insulin human - diabetes mellitus - drogi użati fid-dijabete - trattament tad-dijabete mellitus.
Unjoni Ewropea -
Malti -
EMA (European Medicines Agency)
suliqua
sanofi winthrop industrie - l-insulina glargine, lixisenatide - diabetes mellitus, tip 2 - drogi użati fid-dijabete - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sglt-2 inhibitors.